Biotech Holdings Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Holdings

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dave anderson who wrote (88)	12/11/1997 10:26:00 PM
From: Mike Heimbuch	Read Replies (1) of 224

Dave Glad to see you are following. I passed along the concerns as posted by "Tommysdad" on this board - to Biotech - and discussed at length with them the problems posed by the approach and current status of the company. They are emphatic in their insistence that the threats posed by computer analysis and modeling to create 'sister' compounds and market them in direct competition - is in fact a reality - albeit there are those who don't agree. Thus - the decision to be very closed mouth. Evidently the patents are all pending - and there does not appear to be any glitches in the works - or delays by the company - I am told. With small capitalization and incremental approach to DIAB development - they do not likely have the horsepower for accelerated timeline marketing blitzkriegs - to ward off possible early competition should drug sister cloning of DIAB be a real possibility - particularly if done by a big company. I can say this - the company is in the process of animal testing with their proposed CHINA J/V partner (major N. American pharma already operating in China. Completion is expected in a couple of months. In addition - DIAB was granted (as I understand it) - some exclusive marketing considerations in that country on the basis of being a new class of drug - insulin sensitizer. I don't know the time allowance or its significance. It would seem a logical step - that any China J/V signing like this would inevitably lead to negotiations for promotion and development in N. America. Certainly the Caribbean phase III (there was a China phase III also) brings it closer to this hemisphere and investment community notice. Within the company - and for the few science folks watching closely - the lack of any significant toxicity as the testing has shown - should raise a few eyebrows. I know it is difficult to judge this company on the abstract of their activities - solely because the scientific info is being held so closely. What can I say. Why would a company focus so much energy and time on bringing a diabetes drug to the world - and not promote their stock - unless they really had something? That speculation alone makes this company so very intriguing. All the best Mike H.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next